We are live on ! Find out more

MAIA Biotechnology

MAIA

Market cap $85.2M

1.40 USD

+0.06

4.48%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

1.42

+0.02

1.43%

1 day

4.48%

5 days

2.94%

1 month

0.72%

3 months

6.06%

6 months

-9.09%

Year to date

-12.5%

1 year

-13.04%

5 years

-68.61%

10 years

-68.61%

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Employees: 13

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

Next-generation divalent agents show increased anticancer activity in preclinical in vitro and in vivo models CHICAGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) held in Barcelona, Spain.

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC). Initial data from the THIO-101 Part C 3L studies1 show a disease control rate (DCR) of 90.5% (19 out of 21 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment.

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (“Winship”), is activated and now enrolling patients. The trial studies MAIA's lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $70 billion global non-small cell lung cancer market by 2030 1 CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the second U.S. clinical site in its Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama. The expansion part of THIO-101 evaluates MAIA's lead investigational therapy, ateganosine, a dual-action molecule incorporating telomere targeting and immunogenicity, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC) in patients who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy.

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

See News Rankings

Price charts implemented using Lightweight Charts™